Paclitaxel for the Treatment of Gastric or Gastroesophageal Cancer
Phase 1
Active, not recruiting
- Conditions
- Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8Peritoneal CarcinomatosisPostneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage IV Gastric Cancer AJCC v8Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8
- Interventions
- First Posted Date
- 2020-01-07
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 27
- Registration Number
- NCT04220827
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Vorinostat and Combination Chemotherapy Before Donor Stem Cell Transplantation for the Treatment of Relapsed Aggressive B-cell or T-cell Non-Hodgkin Lymphoma
Phase 2
Withdrawn
- Conditions
- Recurrent T-Cell Non-Hodgkin LymphomaRecurrent Transformed B-Cell Non-Hodgkin LymphomaRecurrent Burkitt LymphomaRecurrent Aggressive Non-Hodgkin LymphomaRecurrent B-Cell Non-Hodgkin LymphomaRecurrent Diffuse Large B-Cell LymphomaRecurrent High Grade B-Cell Lymphoma
- Interventions
- Procedure: Allogeneic Hematopoietic Stem Cell TransplantationDrug: BusulfanDrug: ClofarabineDrug: CyclophosphamideDrug: GemcitabineDrug: Mycophenolate MofetilBiological: RituximabDrug: TacrolimusDrug: Vorinostat
- First Posted Date
- 2020-01-07
- Last Posted Date
- 2024-01-12
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT04220008
PET/MRI Scan for the Evaluation of Resectable Stage IA1-IB3 Cervical Cancer
Early Phase 1
Active, not recruiting
- Conditions
- Stage IA1 Cervical CancerStage IA2 Cervical CancerStage IB2 Cervical CancerStage IB Cervical CancerStage IB3 Cervical CancerStage IA Cervical CancerStage IB1 Cervical Cancer
- Interventions
- Other: Fludeoxyglucose F-18Drug: GadobutrolProcedure: Magnetic Resonance ImagingProcedure: Positron Emission Tomography
- First Posted Date
- 2020-01-07
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 25
- Registration Number
- NCT04219904
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
FDG PET-MRI for the Diagnosis of Spinal Cord Lesions
Not Applicable
Completed
- Conditions
- Spinal Cord Neoplasm
- Interventions
- First Posted Date
- 2020-01-07
- Last Posted Date
- 2024-05-09
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 11
- Registration Number
- NCT04219969
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Bintrafusp Alfa and Stereotactic Body Radiation Therapy for the Treatment of Recurrent or Second Primary Head and Neck Squamous Cell Cancer
Phase 1
Terminated
- Conditions
- Recurrent Head and Neck Squamous Cell CarcinomaSecond Primary Squamous Cell Carcinoma of the Head and Neck
- Interventions
- Drug: Bintrafusp AlfaOther: Quality-of-Life AssessmentOther: Questionnaire AdministrationRadiation: Stereotactic Body Radiation Therapy
- First Posted Date
- 2020-01-07
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 3
- Registration Number
- NCT04220775
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Natural History of Medullary Thyroid Cancer to Inform Advanced Disease Management
Recruiting
- Conditions
- Stage III Thyroid Gland Medullary Carcinoma AJCC v8Stage IV Thyroid Gland Medullary Carcinoma AJCC v8Stage IVB Thyroid Gland Medullary Carcinoma AJCC v8Stage IVA Thyroid Gland Medullary Carcinoma AJCC v8Advanced Thyroid Gland Medullary CarcinomaStage IVC Thyroid Gland Medullary Carcinoma AJCC v8
- Interventions
- Other: Blood Pressure MeasurementOther: Questionnaire Administration
- First Posted Date
- 2020-01-03
- Last Posted Date
- 2024-08-26
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 2030
- Registration Number
- NCT04216732
- Locations
- 🇺🇸
University of California San Francisco, San Francisco, California, United States
🇺🇸M D Anderson Cancer Center, Houston, Texas, United States
Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm
Phase 2
Recruiting
- Conditions
- Blastic Plasmacytoid Dendritic Cell Neoplasm
- Interventions
- First Posted Date
- 2020-01-02
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 40
- Registration Number
- NCT04216524
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
ABL001 for the Treatment of Chronic Myeloid Leukemia in Patients Who Are on Therapy With Tyrosine Kinase Inhibitor
Phase 2
Active, not recruiting
- Conditions
- Philadelphia Chromosome Negative, BCR-ABL1 Positive Chronic Myelogenous Leukemia
- Interventions
- First Posted Date
- 2020-01-02
- Last Posted Date
- 2024-10-28
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 40
- Registration Number
- NCT04216563
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Nab-paclitaxel and Alpelisib for the Treatment of Anthracycline Refractory Triple Negative Breast Cancer With PIK3CA or PTEN Alterations
Phase 2
Active, not recruiting
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8Anatomic Stage IA Breast Cancer AJCC v8Anatomic Stage IB Breast Cancer AJCC v8Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage IIA Breast Cancer AJCC v8Anatomic Stage IIB Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IIIA Breast Cancer AJCC v8Anatomic Stage IIIB Breast Cancer AJCC v8Anatomic Stage IIIC Breast Cancer AJCC v8
- Interventions
- First Posted Date
- 2020-01-02
- Last Posted Date
- 2024-10-28
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 8
- Registration Number
- NCT04216472
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Lifestyle Intervention for the Reduction of Prostate Cancer Disparities Among African Americans
Not Applicable
Active, not recruiting
- Conditions
- Cancer SurvivorPartnerSpouseStage I Prostate Cancer AJCC V8Stage II Prostate Cancer AJCC V8Stage IIA Prostate Cancer AJCC V8Stage IIB Prostate Cancer AJCC V8Stage IIC Prostate Cancer AJCC V8Stage III Prostate Cancer AJCC V8Stage IIIA Prostate Cancer AJCC V8
- Interventions
- Behavioral: Exercise InterventionOther: InterviewOther: Informational InterventionOther: Nutritional AssessmentOther: Questionnaire AdministrationBehavioral: Telephone-Based Intervention
- First Posted Date
- 2020-01-02
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 6
- Registration Number
- NCT04215029
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
© Copyright 2025. All Rights Reserved by MedPath